Telesis Bio Inc

Telesis Bio, Inc. engages in research and development of genomic tools for biomedical and industrial applications. It offers BioXp 3200 system and Gibson assembly reagents. The company was founded by Daniel G. Gibson and J. Craig Venter on March 24, 2011 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Telesis Bio, Inc. engages in the provision of automated multi-omic and synthetic biology solutions. The firm also focuses on providing applications to enable researchers to rapidly, accurately, and reproducibly build or write synthetic DNA and mRNA and short oligonucleotides such as CRISPR guides that are ready to use in many downstream synthetic biology enabled markets. The company was founded by Daniel G. Gibson and J. Craig Venter on March 24, 2011 and is headquartered in San Diego, CA.

-- First inhaled mRNA therapeutic remains on track to report results from its ongoing multiple-ascending dose (MAD) portion of Phase 1/2 clinical trial in the third quarter of 2020 --  LEXINGTON, Mass., Feb.  26, 2020  (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for MRT5005 for the treatment of cystic fibrosis (CF).  MRT5005, the first mRNA therapeutic with delivery to the lung, is designed to address the underlying cause of CF, regardless of genetic mutation, by delivering mRNA encoding fully functional cystic fibrosis transmembrane conductance regulator (CFTR) protein to cells in the lung through nebulization. The Phase 1/2 clinical trial of MRT5005 is currently ongoing.

Translate Bio Receives FDA Fast Track Designation for MRT5005 for the Treatment of  Cystic Fibrosis

-- Appointment of Frank DeRosa, Ph.D. to Chief Technology Officer, and transition of Michael Heartlein, Ph.D. to Executive Vice President and Founder --    -- Appointment of Paul Burgess to Chief Operating Officer --

Translate Bio Announces Executive Leadership Appointments

Aerie Pharmaceuticals

Akebia Therapeutics

Cytokinetics

Novavax

For investors seeking out the ultimate high-risk, high-reward stocks, look no further than the biotech industry.

5 “Strong Buy” Biotech Stocks With More Than 80% Upside

Translate Bio, Inc. (TBIO) delivered earnings and revenue surprises of 8.89% and -28.31%, respectively, for the quarter ended September 2019.

Translate Bio, Inc. (TBIO) Reports Q3 Loss, Lags Revenue Estimates

Translate Bio is set to present an oral and poster presentation for its phase 1/2 data using MRT5005 to treat patients with cystic fibrosis at an upcoming medical conference.

Translate Bio Should Be On Your Radar With Upcoming Presentation And CF Data In 2020

LEXINGTON, Mass., Oct.  01, 2019  (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced upcoming oral and poster presentations on MRT5005, an inhaled mRNA therapeutic, at the 33rd Annual North American Cystic Fibrosis Conference (NACFC) taking place in Nashville, Tennessee from October 31 to November 2, 2019.

Translate Bio Announces Upcoming MRT5005 Presentations at the 33rd Annual North American Cystic Fibrosis Conference

LEXINGTON, Mass., Sept.  30, 2019  (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that Ronald Renaud, chief executive officer, will participate in a fireside chat at the 3rd Annual Chardan Genetic Medicines Conference in New Yok, NY, on Monday, October 7, 2019, at 11:00 a.m. ET.

Translate Bio to Present at the 3rd Annual Chardan Genetic Medicines Conference

Biogen

Moderna

Unfilled promises by biotechs can lead to broken hearts for investors.

Messenger RNA Is Just the Latest Siren Song From Biotech: Don’t Listen

After expanding his position in Translate Bio Inc. (NASDAQ:TBIO) at the end of August, Baupost Group leader Seth Klarman (Trades, Portfolio) disclosed on Friday that he boosted the stake another 42.96%.

Seth Klarman Further Increases Translate Bio Stake

The company announced a stock offering to raise cash, but today's drop could've been much worse.

Here's Why Translate Bio Dropped Today

LEXINGTON, Mass., Sept.  17, 2019  (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the pricing of its underwritten public offering of 9,000,000 shares of its common stock at a public offering price of $10.00 per share, for aggregate gross proceeds of $90 million, before deducting underwriting discounts and commissions and offering expenses payable by Translate Bio. In addition, Translate Bio has granted the underwriters a 30-day option to purchase up to 1,350,000 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares are being sold by Translate Bio. The offering is expected to close on September 20, 2019, subject to the satisfaction of customary closing conditions.

Translate Bio  Announces Pricing of Public Offering of Common Stock

LEXINGTON, Mass., Sept.  17, 2019  (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that it has commenced an underwritten public offering of $90 million of its common stock. Translate Bio also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the public offering. All of the shares are being offered by Translate Bio.

Translate Bio Announces Proposed  Public Offering of Common Stock

--  Agreement provides Translate Bio with customized and dedicated manufacturing space for cGMP mRNA production for current and future programs --   LEXINGTON, Mass., Sept.  12, 2019  (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that it has entered into a multi-year strategic manufacturing agreement with Albany Molecular Research, Inc. (AMRI), a best-in-class, global clinical development manufacturing organization, in support of the planned expansion of Translate Bio’s current Good Manufacturing Practices (cGMP) clinical mRNA manufacturing capabilities.

Translate Bio Announces Strategic Manufacturing Agreement with AMRI in Support of Messenger RNA (mRNA) Manufacturing

Baupost Group founder Seth Klarman (Trades, Portfolio) disclosed on Monday he expanded his stake in Translate Bio Inc.

Baupost’s Seth Klarman Dives Further Into Translate Bio

- Prioritizing and expanding pulmonary disease programs based on early positive cystic fibrosis (CF) data for MRT5005, the first inhaled mRNA therapeutic –

Translate Bio Announces Pipeline Program Update

Translate Bio, Inc. (TBIO) delivered earnings and revenue surprises of -26.67% and -32.26%, respectively, for the quarter ended June 2019.

Translate Bio, Inc. (TBIO) Reports Q2 Loss, Lags Revenue Estimates

Shares of the clinical-stage mRNA therapeutics company Translate Bio Inc (NASDAQ: TBIO), which went public in June 2018, were showing some strength Wednesday.

FDA Lifts Clinical Hold On Translate Bio's Liver Disorder Trial

Bristol-Myers

Celgene

Takeda Pharmaceutical

The most prominent positions in Seth Klarman (Trades, Portfolio) equity portfolio are well-known and covered by the financial media.

Seth Klarman's Favorite Biotech Positions

News for Telesis Bio Inc Stock (TBIO)